Eupraxia Pharmac SEC Filings

Eupraxia Pharmaceuticals Inc. submitted a Form 6-K as a foreign private issuer to confirm an administrative step related to its upcoming shareholder matters. The company’s transfer agent, TSX Trust Company, states that proxy-related materials were mailed on May 27, 2026 to Registered Securityholders and ESP Holders. This filing simply documents that the required proxy documents have been distributed.

Eupraxia Pharmaceuticals Inc. filed a Form 6-K to share that its management team will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 3, 2026, from 5:30PM to 6:00PM in New York, with 1x1 investor meetings on June 3 and 4.

Eupraxia is a clinical-stage biotechnology company developing locally delivered, extended-release treatments using its proprietary Diffusphere™ micro-sphere technology. Its pipeline includes EP-104GI in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis and EP-104IAR, which met the primary endpoint in a Phase 2b knee osteoarthritis pain trial.

EUPRAXIA PHARMACEUTICALS INC. ownership disclosure: Manchester Management entities and associated individuals report beneficial holdings in Common Shares as of 03/31/2026.

Manchester Management Company, LLC and Manchester Management PR, LLC each report 3,830,869 shares (7.4%); Manchester Explorer, L.P. reports 3,707,942 shares (7.1%). James E. Besser reports 3,969,162 shares (7.6%) and Morgan C. Frank reports 4,015,248 shares (7.7%).

Eupraxia Pharmaceuticals Inc. reported a larger net loss for the three months ended March 31, 2026 as it accelerated spending on its EP-104 pipeline. Net loss was $12.7 million compared with $6.8 million a year earlier, driven mainly by higher research and development and corporate costs.

Research and development expenses more than doubled to $11.2 million, reflecting expanded clinical activity in eosinophilic esophagitis and related programs, while general and administrative expenses rose to $4.8 million. To support this growth, Eupraxia completed a February 2026 equity financing, raising roughly $63.2 million gross through common shares and pre-funded warrants.

Despite the higher loss, the company ended the quarter with a substantial cash position: cash and cash equivalents of $58.5 million and short-term investments of $80.4 million, backing ongoing Phase 1b/2 work in EP-104GI and strategic options for EP-104IAR. Management continues to emphasize the need for future financings or partnerships to fund later-stage trials and potential commercialization.

Eupraxia Pharmaceuticals reported new tissue-based results from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis (EoE). Using the EoE Histology Scoring System (EoEHSS), inflammation sub scores improved in all reported cohorts at 12 weeks (n=31) and 36 weeks (n=27).

Tissue architecture and fibrosis sub scores also improved across most cohorts. At the highest dose cohort, grade and stage improvements in inflammatory scores exceeded 90%, and architectural/fibrotic scores improved by more than 83% at both 12 and 36 weeks. These findings align with earlier symptom and endoscopic (EREFS) improvements.

The open-label dose-escalation portion of RESOLVE follows patients up to 24 or 52 weeks, depending on cohort. A randomized, placebo-controlled Phase 2b part of RESOLVE is now recruiting 120 mg and 160 mg doses of EP-104GI, with top-line data expected in Q4 2026.

Eupraxia Pharmaceuticals reported new endoscopic EREFS data from the Phase 1b/2a part of its RESOLVE trial of EP-104GI in eosinophilic esophagitis (EoE). The company presented the results at Digestive Disease Week in Chicago.

Among participants with baseline EREFS scores above 2, the share of responders (scores ≤2) at week 12 rose with more esophageal injections. In 7 patients who received 20 injections, mean EREFS fell 65% (3.6 points), with near-complete improvement in the highest-dose cohorts. These findings support using 20 injections in the ongoing placebo-controlled Phase 2b trial, which is enrolling 120mg (20x6mg) and 160mg (20x8mg) doses with top-line data expected in Q4 2026.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding retiring CMO Dr. Mark Kowalski, who will remain as a senior consultant during the transition. Dr. Tambiah brings over 18 years of biopharmaceutical clinical development, medical and regulatory strategy, and commercialization experience, particularly in immunology and late-stage programs.

The company is advancing EP-104GI for Eosinophilic Esophagitis in its RESOLVE Phase 1b/2 trial and previously completed the SPRINGBOARD Phase 2b trial of EP-104IAR for knee osteoarthritis, which met its primary endpoint and most secondary endpoints. Eupraxia’s Diffusphere™ technology is designed for targeted, extended-release, locally delivered therapies in areas of high unmet medical need.

Eupraxia Pharmaceuticals Inc. is highlighting new clinical data for its lead candidate EP-104GI in eosinophilic esophagitis at the Digestive Disease Week 2026 conference. The company will present one oral and three poster abstracts from the ongoing Phase 1b/2 RESOLVE trial, including 36‑week histology, endoscopy and symptom durability results.

Eupraxia will also host a virtual investor event on May 4, 2026, featuring key opinion leaders discussing recurrent esophageal strictures and the potential of EP-104GI, a long-acting submucosal corticosteroid injection. The filing also notes earlier success of EP-104IAR, which met its primary endpoint in a Phase 2b knee osteoarthritis trial.

Eupraxia Pharmaceuticals reported new 36‑week results from the highest dose cohort (Cohort 9, n=3) of its Phase 1b/2a RESOLVE trial testing EP‑104GI in eosinophilic esophagitis. Patients showed robust, sustained improvements in both tissue health and swallowing symptoms compared with their own baselines.

EoEHSS Stage and Grade scores in Cohort 9 improved by 0.59 and 0.53 at week 36, corresponding to 90% and 88% reductions, with benefits seen in both inflammatory and structural components. Peak Eosinophil Count fell 72% from baseline, the largest reduction among all dose levels.

Symptoms, measured by the Straumann Dysphagia Index, improved by an average of 3 points at week 36, meeting the trial’s definition of clinical remission; 2 of 3 patients maintained remission from weeks 8 through 36. Across 31 patients and more than 230 patient‑months of follow‑up, EP‑104GI has been generally well tolerated with no drug‑related serious adverse events, no oropharyngeal candidiasis, and no adrenal or glucose derangements. A placebo‑controlled Phase 2b portion of RESOLVE using high doses is ongoing, with top‑line data expected in Q4 2026.